Download fulltext HTML
Anggraeni, A. D., & Muchlisin, M. A. (2022). Activity of Secondary Metabolites of Momordica Charantia as a DNA Gyrase Inhibitor of Helicobacter Pylori: Homology Modelling and Molecular Docking. KnE Medicine, 2(3), 480–488. https://doi.org/10.18502/kme.v2i3.11901

https://doi.org/10.18502/kme.v2i3.11901

statistics

  • 232 Abstract Views
  • 136 PDF Views
  • 0 HTML Views

authors

  • Amaliyah Dina Anggraeni

    Amaliyah Dina Anggraeni

    Department of Pharmacy, Faculty of Health Science, University of Muhammadiyah Malang
  • M. Artabah Muchlisin

    M. Artabah Muchlisin

    Department of Pharmacy, Faculty of Health Science, University of Muhammadiyah Malang

Published Date

  • Sep 15, 2022

Activity of Secondary Metabolites of Momordica Charantia as a DNA Gyrase Inhibitor of Helicobacter Pylori: Homology Modelling and Molecular Docking

KnE Medicine / The International Conference of Medicine and Health (ICMEDH) / Pages 480–488

Abstract

Helicobacter pylori can induce gastritis, ulcers, and gastric cancer. H. pylori is also responsible for causing oropharynx, endocrine, respiratory, central nervous system, eye, and reproductive system diseases. Treatment of H. pylori includes relieving gastritis or pain but this is not specific for H. pylori. Therefore, it is necessary to develop drugs of new therapeutic molecules to treat H. pylori. The purpose of this study was to determine which metabolite compounds from the Momordica charantia plant could provide activity as a DNA gyrase inhibitor. The target protein used in this study was prepared using the homology modeling method with the SWISS-MODEL web tools. Secondary metabolite compounds of M. charantia were processed using SwissADME web tools to find predictions for their pharmacokinetic profiles. The secondary metabolite compounds used for molecular docking using autodock 4.2 were compounds in the BOILED-Egg method range. From the homology modeling results, the quaternary structure quality estimate was 0.57 and the global mean quality estimate was 0.52. From the BOILED-Egg, six compounds were predicted to have good bioavailability. The molecular docking found that diosgenin had the lowest binding free energy (-5.35 kcal/mol) and inhibition constant (119.52 uM), so it was predicted that diosgenin could be used as an inhibitor of DNA gyrase in H. pylori.


Keywords: Helicobacter pylori, DNA gyrase, Momordica charantia, homology modelling, molecular docking

References
[1] Gravina AG, Zagari RM, De Musis C, Romano L, Loguercio C, Romano M. Helicobacter pylori and extragastric diseases: A review. World Journal of Gastroenterology. 2018;24(29):3204–3221.


[2] Bravo D, Hoare A, Soto C, Valenzuela MA, Quest AF. Helicobacter pylori in human health and disease: Mechanisms for local gastric and systemic effects. World Journal of Gastroenterology. 2018;24(28):3071–3089.


[3] Salama NR, Hartung ML, Müller A. Life in the human stomach: Persistence strategies of the bacterial pathogen Helicobacter pylori. Nature Reviews Microbiology. 2013;11(6):385–399.


[4] Hooi JKY, Lai WY, Ng WK, et al. Global prevalence of helicobacter pylori infection: Systematic review and meta-analysis. Gastroenterology. 2017;2:420–429.


[5] Petersen AM, Krogfelt KA. Helicobacter pylori: An invading microorganism? A review. FEMS Immunology & Medical Microbiology. 2003;36(3):117–126.


[6] Kusmana C, Hikmat A. The biodiversity of flora in Indonesia. Journal of Natural Resources and Environmental Management. 2015;5(2):187–198.


[7] Zaini WS, Kunci K. Abstrak. 2017;4(November):147–156.


[8] Raish M, Ahmad A, Ansari MA, et al. Momordica charantia polysaccharides. ameliorate oxidative stress, inflammation, and apoptosis in ethanol-induced gastritis in mucosa through NF-kB signaling pathway inhibition. International Journal of Biological Macromolecules. 2018;111:193–199.


[9] Li Z, Xia A, Li S, et al. The pharmacological properties and therapeutic use of bitter melon (Momordica charantia L.). Current Pharmacology Reports. 2020;6(3):103–109.


[10] Dr Duke. Dr. Duke’s phytochemical and ethnobotanical databases. USDA; 2020.


[11] Medicinal Plants of India. Indian Council on Medical Research; 1976.


[12] Watt JM, Breyer Brandwijk MG. The medicinal and poisonous plants of southern and eastern Africa. Edinburgh, UK: E. & S. Livingstone Ltd.; 1967.


[13] Hanwell MD, Curtis DE, Lonie DC, Vandermeersch T, Zurek E, Hutchison GR. Avogadro: An advanced semantic chemical editor, visualization, and analysis platform. Journal of Cheminformatics. 2012;4(1):17.


[14] Daina A, Michielin O, Zoete V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports. 2017;7(1):42717.


[15] Daina A, Zoete V. A boiled-egg to predict gastrointestinal absorption and brain penetration of small molecules. ChemMedChem. 2016;11(11):1117–1121.


[16] Waterhouse A, Bertoni M, Bienert S, et al. SWISS-MODEL: Homology modelling of protein structures and complexes. Nucleic Acids Research. 2018;46(W1):W296– W303.


[17] GenBank [Internet]. Bethesda (MD): National Library of Medicine. USA: National Center for Biotechnology Information; 2004.


[18] Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK. Autodock4 and AutoDockTools4: Automated docking with selective receptor flexiblity. Journal of Computational Chemistry. 2009;16:2785–2791.


[19] Dallakyan S, Olson AJ. Small-molecule library screening by docking with PyRx. Methods in Molecular Biology. 2015;1263:243–250.


[20] Consortium TU. UniProt: A worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47(D1):D506–D515.


[21] BIOVIA. San Diego: Dassault Systèmes; 2019.


[22] Benkert P, Biasini M, Schwede T. Toward the estimation of the absolute quality of. individual protein structure models. Bioinformatics. 2011;27(3):343–350.